Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Cancer Research

• Publication date

  2006-08-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-05-2769PMID 16912192PMCID PMC2924674
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Molecular biology of neuroblastoma

  2007cited by this paper
• Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants

  2005cited by this paper
• The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma.

  2005influential reference
• Disruption of Cooperation Between Ras and MycN in Human Neuroblastoma Cells Promotes Growth Arrest

  2005cited by this paper
• The Life Cycle of C-Myc: From Synthesis to Degradation

  2004cited by this paper
• A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells

  2004cited by this paper
• Phosphatidylinositol 3-kinase inhibition down-regulates survivin and facilitates TRAIL-mediated apoptosis in neuroblastomas.

  2004cited by this paper
• Dual regulation of Snail by GSK-3β-mediated phosphorylation in control of epithelial–mesenchymal transition

  2004cited by this paper
• Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold.

  2004cited by this paper
• GSK3-mediated BCL-3 phosphorylation modulates its degradation and its oncogenicity.

  2004cited by this paper
• Hedgehog and PI-3 kinase signaling converge on Nmyc1 to promote cell cycle progression in cerebellar neuronal precursors

  2004cited by this paper
• Genome-wide array CGH analysis of murine neuroblastoma reveals distinct genomic aberrations which parallel those in human tumors.

  2003cited by this paper
• Phosphoinositide 3-kinase signalling--which way to target?

  2003cited by this paper
• Use of high-performance liquid chromatography to characterize the rapid decomposition of wortmannin in tissue culture media.

  2003cited by this paper
• Effects of MYCN antisense oligonucleotide administration on tumorigenesis in a murine model of neuroblastoma.

  2003cited by this paper
• Rapamycin inhibits proliferation of human neuroblastoma cells without suppression of MycN

  2003cited by this paper
• Phosphorylation by Glycogen Synthase Kinase-3 Controls c-Myc Proteolysis and Subnuclear Localization*

  2003cited by this paper
• Nmyc upregulation by sonic hedgehog signaling promotes proliferation in developing cerebellar granule neuron precursors

  2003cited by this paper
• Neuroblastoma: biological insights into a clinical enigma

  2003cited by this paper
• Minichromosome maintenance protein MCM7 is a direct target of the MYCN transcription factor in neuroblastoma.

  2002cited by this paper
• Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study.

  2000cited by this paper
• MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN.

  2000cited by this paper
• Genome-wide screen for allelic imbalance in a mouse model for neuroblastoma.

  2000cited by this paper
• The N-myc oncogene in human neuroblastoma cells: down-regulation of an angiogenesis inhibitor identified as activin A.

  2000cited by this paper
• c-Myc Proteolysis by the Ubiquitin-Proteasome Pathway: Stabilization of c-Myc in Burkitt's Lymphoma Cells

  2000cited by this paper
• MYCN oncogene and angiogenesis: down-regulation of endothelial growth inhibitors in human neuroblastoma cells. Purification, structural, and functional characterization.

  2000cited by this paper
• N-Myc induction stimulated by insulin-like growth factor I through mitogen-activated protein kinase signaling pathway in human neuroblastoma cells.

  2000cited by this paper
• Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival.

  1999cited by this paper
• Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic Acid

  1999cited by this paper
• Molecular biology of neuroblastoma.

  1999cited by this paper
• Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group.

  1999cited by this paper
• Targeted expression of MYCN causes neuroblastoma in transgenic mice

  1997cited by this paper
• β‐catenin is a target for the ubiquitin–proteasome pathway

  1997cited by this paper
• Modulation of N-myc expression alters the invasiveness of neuroblastoma

  1997cited by this paper
• beta-catenin is a target for the ubiquitin-proteasome pathway.

  1997cited by this paper
• Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells.

  1996influential reference
• Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma.

  1996cited by this paper
• Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma.

  1996cited by this paper
• Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B

  1995cited by this paper
• A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002).

  1994cited by this paper
• The biological effects of antisense N-myc expression in human neuroblastoma.

  1994cited by this paper
• Inhibition of histamine secretion by wortmannin through the blockade of phosphatidylinositol 3-kinase in RBL-2H3 cells.

  1993cited by this paper
• Regulation of insulin‐like growth factor‐II expression and its role in autocrine growth of human neuroblastoma cells

  1993cited by this paper
• The N-myc proto-oncogene: developmental expression and in vivo site-directed mutagenesis.

  1992cited by this paper
• Decrease of proliferation rate and induction of differentiation by a MYCN antisense DNA oligomer in a human neuroblastoma cell line.

  1991cited by this paper
• The N‐myc Proto‐oncogene: Developmental Expression and in vivo Site‐Directed Mutagenesis

  1991cited by this paper
• Augmented MYCN expression advances the malignant phenotype of human neuroblastoma cells: evidence for induction of autocrine growth factor activity.

  1990cited by this paper
• Prolonged N-myc protein half-life in a neuroblastoma cell line lacking N-myc amplification.

  1990cited by this paper
• Principles and Practice of Pediatric Oncology

  1989cited by this paper
• Tissue and age specific expression of the myc proto-oncogene family throughout the life span of the C57BL/6J mouse strain.

  1989cited by this paper
• Differential expression of myc family genes during murine development

  1986influential reference
• Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma

  1985cited by this paper
• Amplification of N-myc sequences in primary human neuroblastomas: correlation with advanced disease stage.

  1985cited by this paper
• Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas.

  1985cited by this paper
• Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage.

  1984cited by this paper

• Clinical management and therapeutic development for the rare disease rhabdomyosarcoma

  2026cites this paper
• 15 Years Old ALK Gene from Birth to Adolescence; Where to in NBL

  2025cites this paper
• Myc family proteins: Molecular drivers of tumorigenesis and resistance in neuroendocrine tumors.

  2025cites this paper
• A Phase 1 Trial of Fimepinostat in Children and Adolescents With Relapsed and Refractory Solid and CNS Tumors

  2025cites this paper
• Emerging clinical and research approaches in targeted therapies for high-risk neuroblastoma

  2025cites this paper
• Fimepinostat is a dual inhibitor of tumor and angiogenesis in glioblastoma and synergizes with temozolomide through suppressing MYC

  2025cites this paper
• Unveiling Tumorigenesis Mechanisms and Drug Therapy in Neuroblastoma by Mass Spectrometry Based Proteomics

  2024cites this paper
• Preclinical Therapeutic Efficacy of RAF/MEK/ERK and IGF1R/AKT/mTOR Inhibition in Neuroblastoma

  2024cites this paper
• Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3β inhibitors in children and adolescents with cancer.

  2024cites this paper
• Investigating the molecular mechanisms of Fuzheng Yiliu Shenji prescription in SH-SY5Y neuroblastoma cells

  2024cites this paper
• Kinases Controlling Stability of the Oncogenic MYCN Protein.

  2023cites this paper
• Targeting the MYCN-MDM2 pathways for cancer therapy: Are they druggable?

  2023cites this paper
• IGF1R Contributes to Cell Proliferation in ALK-Mutated Neuroblastoma with Preference for Activating the PI3K-AKT Signaling Pathway

  2023cites this paper
• AKT inhibitor Hu7691 induces differentiation of neuroblastoma cells

  2023cites this paper
• Metabolic protein kinase signalling in neuroblastoma

  2023cites this paper
• The dual HDAC and PI3K inhibitor, CUDC-907, inhibits tumor growth and stem-like properties by suppressing PTX3 in neuroblastoma

  2023cites this paper
• A Review of the Regulatory Mechanisms of N-Myc on Cell Cycle

  2023cites this paper
• A novel cuproptosis-related subtypes and gene signature associates with immunophenotype and predicts prognosis accurately in neuroblastoma

  2022cites this paper
• Targeting ARHGEF12 promotes neuroblastoma differentiation, MYCN degradation, and reduces tumorigenicity

  2022cites this paper
• Inhibition of PI3 kinase isoform p110α suppresses neuroblastoma growth and induces the reduction of Anaplastic Lymphoma Kinase

  2022cites this paper
• A Drug Repurposing Screen Identifies Fludarabine Phosphate as a Potential Therapeutic Agent for N-MYC Overexpressing Neuroendocrine Prostate Cancers

  2022cites this paper
• The MYCN inhibitor BGA002 restores the retinoic acid response leading to differentiation or apoptosis by the mTOR block in MYCN-amplified neuroblastoma

  2022cites this paper
• Synergistic Anti-Tumor Effect of Combining Selective CDK7 and BRD4 Inhibition in Neuroblastoma

  2022cites this paper
• Identification and Characterization of a Glucometabolic Prognostic Gene Signature in Neuroblastoma based on N6-methyladenosine Eraser ALKBH5

  2022cites this paper
• Polymeric nanomedicine for overcoming resistance mechanisms in hedgehog and Myc-amplified medulloblastoma.

  2021cites this paper
• Integrated Genomic Profiling and Drug Screening of Patient-Derived Cultures Identifies Individualized Copy Number-Dependent Susceptibilities Involving PI3K Pathway and 17q Genes in Neuroblastoma

  2021cites this paper
• Post-Translational Regulation of the Activity of ERK/MAPK and PI3K/AKT Signaling Pathways in Neuroblastoma Cancer

  2021cites this paper
• Biological Role of MYCN in Medulloblastoma: Novel Therapeutic Opportunities and Challenges Ahead

  2021cites this paper
• Drug combinations: A strategy to enhance anti-tumor activity and overcome drug resistance to ALK inhibitors in neuroblastoma

  2021cites this paper
• Effects of PI3K and FGFR inhibitors alone and in combination, and with/without cytostatics in childhood neuroblastoma cell lines

  2021cites this paper
• Differential expression of αVβ3 and αVβ6 integrins in prostate cancer progression

  2021cites this paper
• Comparing mTOR inhibitor Rapamycin with Torin-2 within the RIST molecular-targeted regimen in neuroblastoma cells

  2021cites this paper
• MYC inhibitors in multiple myeloma

  2021cites this paper
• Targeting MYCN in Pediatric and Adult Cancers

  2021cites this paper
• Combine Detection of Copy Number Variations of MYCN and ALK using Droplet Digital PCR Identify High Risk Neuroblastoma Patients.

  2021cites this paper
• Development of a cell-based pathway modulator screening system to screen the targeted cancer therapeutic candidates

  2021cites this paper
• PHA-680626 Is an Effective Inhibitor of the Interaction between Aurora-A and N-Myc

  2021cites this paper
• A Focused Small-Molecule Screen Identifies PHA-680626 as an Amphosteric Inhibitor Disrupting the Interaction between Aurora-A and N-Myc

  2021influential citation
• Therapeutic targeting of KSP in preclinical models of high-risk neuroblastoma

  2020cites this paper
• New targeted therapies for malignant neural tumors From systematic discovery to zebrafish models

  2020influential citation
• Targeting Functional Activity of AKT Has Efficacy against Aggressive Neuroblastoma.

  2020cites this paper
• The ETS transcription factor ETV5 is a target of activated ALK in neuroblastoma contributing to increased tumour aggressiveness

  2020cites this paper
• Targeting the Tumor Microenvironment in Neuroblastoma: Recent Advances and Future Directions

  2020cites this paper
• Molecular targeting therapies for neuroblastoma: Progress and challenges

  2020cites this paper
• Nanotechnologoical based miRNA intervention in the therapeutic management of neuroblastoma.

  2019cites this paper
• Aurora A kinase inhibition destabilizes PAX3-FOXO1 and MYCN and synergizes with Navitoclax to induce Rhabdomyosarcoma cell death.

  2019cites this paper
• Anti‐tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL‐302 in neuroblastoma

  2019influential citation
• Acyclic Retinoid Combined With Tenascin-C-derived Peptide Reduces the Malignant Phenotype of Neuroblastoma Cells Through N-Myc Degradation

  2019cites this paper
• Identification and characterization of small molecules targeting MYC function

  2019cites this paper
• Neuroblastoma Pathogenesis

  2019cites this paper
• Current and Future Strategies for Treatment of Relapsed Neuroblastoma

  2019cites this paper
• ALK inhibition with up-front chemotherapy in ALK-positive neuroblastoma patients

  2019cites this paper
• Targeting MYCN and ALK in resistant and relapsing neuroblastoma

  2019cites this paper
• Analyses of FGFR3 and PIK3CA mutations in neuroblastomas and the effects of the corresponding inhibitors on neuroblastoma cell lines.

  2019cites this paper
• Neuroblastoma

  2018cites this paper
• CRISPR/Cas9 nickase mediated targeting of urokinase receptor gene inhibits neuroblastoma cell proliferation

  2018cites this paper
• The HDAC6 inhibitor C1A modulates autophagy substrates in diverse cancer cells and induces cell death

  2018cites this paper
• Too many targets, not enough patients: rethinking neuroblastoma clinical trials

  2018cites this paper
• MYCN Silencing as Therapeutics for Neuroblastoma using RNA interference

  2018cites this paper
• Sphingadienes show therapeutic efficacy in neuroblastoma in vitro and in vivo by targeting the AKT signaling pathway

  2018cites this paper
• Nobiletin Enhances Chemosensitivity to Adriamycin through Modulation of the Akt/GSK3β/β–Catenin/MYCN/MRP1 Signaling Pathway in A549 Human Non-Small-Cell Lung Cancer Cells

  2018cites this paper
• Molecularly Targeted Therapy for Neuroblastoma

  2018cites this paper
• ALK positively regulates MYCN activity through repression of HBP1 expression

  2018cites this paper
• Molecular mechanisms and therapeutic targets in neuroblastoma

  2018cites this paper
• Prognostic significance of MYCN gene amplification and protein expression in primary brain tumors: Astrocytoma and meningioma

  2017cites this paper
• Association with Aurora-A Controls N-MYC-Dependent Promoter Escape and Pause Release of RNA Polymerase II during the Cell Cycle

  2017cites this paper
• p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy

  2017cites this paper
• A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers.

  2017cites this paper
• N-Myc Inhibition: Advances in Neuroblastoma Treatment

  2017cites this paper
• Association of high microvessel αvβ3 and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126.

  2017cites this paper
• The MYCN Protein in Health and Disease

  2017cites this paper
• Rho-associated kinase is a therapeutic target in neuroblastoma

  2017cites this paper
• Advances in ALK Targeted Therapy for Neuroblastoma

  2017cites this paper
• MiRNA-124-3p Reduces Cell Viability in Cisplatin Resistant Neuroblastoma Cell Models.

  2017cites this paper
• Emerging and investigational therapies for neuroblastoma

  2017cites this paper
• CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2

  2017cites this paper
• Early and late effects of pharmacological ALK inhibition on the neuroblastoma transcriptome

  2017cites this paper
• Overexpression of pyruvate dehydrogenase kinase 1 in retinoblastoma: A potential therapeutic opportunity for targeting vitreous seeds and hypoxic regions

  2017cites this paper
• Molecular Genetics of Neuroblastoma

  2017cites this paper
• MYC Modulation around the CDK2/p27/SKP2 Axis

  2017cites this paper
• Microarray expression analysis of MYCN-amplified neuroblastoma cells after inhibition of CDK2.

  2017cites this paper
• Class II Phosphoinositide 3-Kinases as Novel Drug Targets.

  2017cites this paper
• Didymin: an orally active citrus flavonoid for targeting neuroblastoma

  2017cites this paper
• ZAR1 knockdown promotes the differentiation of human neuroblastoma cells by suppression of MYCN expression

  2017cites this paper
• Neuroblastoma treatment in the post-genomic era

  2017cites this paper
• Novel Approaches to Apoptosis-Inducing Therapies.

  2016cites this paper
• BarTeL, a Genetically Versatile, Bioluminescent and Granule Neuron Precursor-Targeted Mouse Model for Medulloblastoma

  2016cites this paper
• Einfluss der Galectin-1 Expression auf die Tumor-Immun-Interaktion im Neuroblastom

  2016cites this paper
• Association of high microvessel αvβ3 and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126

  2016cites this paper
• N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.

  2016cites this paper
• Novel pharmacodynamic biomarkers for MYCN protein and PI3K/AKT/mTOR pathway signaling in children with neuroblastoma

  2016cites this paper
• VIP and PACAP analogs regulate therapeutic targets in high-risk neuroblastoma cells.

  2016cites this paper
• Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors

  2016cites this paper
• BRG1/SMARCA4 is essential for neuroblastoma cell viability through modulation of cell death and survival pathways

  2016cites this paper
• The PI3K/Akt Pathway in Tumors of Endocrine Tissues

  2016influential citation
• Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment

  2015cites this paper
• Molecular and In Vivo Characterization of Cancer-Propagating Cells Derived from MYCN-Dependent Medulloblastoma

  2015cites this paper
• GD 2 ganglioside specific antibody treatment downregulates PI 3 K / Akt / mTOR signaling network in human neuroblastoma cell lines

  2015influential citation
• Advances in Risk Classification and Treatment Strategies for Neuroblastoma.

  2015cites this paper
• Dual PI3K/mTOR inhibition with BEZ235 augments the therapeutic efficacy of doxorubicin in cancer without influencing cardiac function

  2015cites this paper